Healthcare utilization and hydroxyurea adherence in youth with sickle cell disease

Sherif M Badawy*, Alexis A Thompson, Jane Louise Holl, Frank J. Penedo, Robert I Liem

*Corresponding author for this work

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Sickle cell disease (SCD) complications lead to poor health-related quality of life (HRQOL) and increased healthcare utilization in this population, which could be mitigated with hydroxyurea therapy; however, adherence is suboptimal. We assessed the relationship of healthcare utilization to hydroxyurea adherence and HRQOL amongst youth with SCD. Methods: Thirty-four patients with SCD (median age 14 years, IQR 12–18) on hydroxyurea participated in this cross-sectional study and completed Morisky Adherence Scale 8-items and Patient Reported Outcomes Measurement Information System (PROMIS®) HRQOL measures. A medical chart review was conducted to assess healthcare utilization. Results: Participants with more frequent hospitalizations and emergency room (ER) visits and longer length of stay (LOS) had significantly lower fetal hemoglobin (r s =–0.44; r s =–0.45; r s =–0.46, p < 0.05) and mean corpuscular volume (r s =–0.47; r s =–0.42; r s =–0.48, p < 0.05), respectively. More frequent hospitalizations and ER visits and longer LOS correlated significantly with worse fatigue (r s =0.51; r s =0.41; r s =0.53, p < 0.05), pain (r s =0.41; r s =0.38; r s =0.47, p < 0.05), physical function mobility (r s =–0.67; r s =–0.59; r s =–0.67, p < 0.05), depression (r s =0.38; r s =0.31; r s =0.42, p < 0.05), and social isolation (r s =0.76; r s =0.76; r s =–0.84, p < 0.05), respectively. Conclusions: We conclude that increased healthcare utilization in youth with SCD is associated with low adherence to hydroxyurea and worse HRQOL domain scores. It is important emphasize the clinical benefits of high adherence to hydroxyurea, particularly among youth with SCD. Future longitudinal studies are warranted to assess the directionality of these relationships, and may reveal modifiable behavioral factors associated with early changes in hydroxyurea adherence levels.

Original languageEnglish (US)
Pages (from-to)297-308
Number of pages12
JournalPediatric Hematology and Oncology
Volume35
Issue number5-6
DOIs
StatePublished - Aug 18 2018

Fingerprint

Hydroxyurea
Sickle Cell Anemia
Delivery of Health Care
Quality of Life
Hospital Emergency Service
Length of Stay
Hospitalization
Fetal Hemoglobin
Social Isolation
Erythrocyte Indices
Information Systems
Fatigue
Longitudinal Studies
Cross-Sectional Studies
Depression
Pain
Population

Keywords

  • Sickle cell disease
  • adherence
  • healthcare utilization
  • hydroxyurea
  • quality of life

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

@article{a16d5b9435b04a6d9cbbabb9a27a4616,
title = "Healthcare utilization and hydroxyurea adherence in youth with sickle cell disease",
abstract = "Background: Sickle cell disease (SCD) complications lead to poor health-related quality of life (HRQOL) and increased healthcare utilization in this population, which could be mitigated with hydroxyurea therapy; however, adherence is suboptimal. We assessed the relationship of healthcare utilization to hydroxyurea adherence and HRQOL amongst youth with SCD. Methods: Thirty-four patients with SCD (median age 14 years, IQR 12–18) on hydroxyurea participated in this cross-sectional study and completed Morisky Adherence Scale 8-items and Patient Reported Outcomes Measurement Information System (PROMIS{\circledR}) HRQOL measures. A medical chart review was conducted to assess healthcare utilization. Results: Participants with more frequent hospitalizations and emergency room (ER) visits and longer length of stay (LOS) had significantly lower fetal hemoglobin (r s =–0.44; r s =–0.45; r s =–0.46, p < 0.05) and mean corpuscular volume (r s =–0.47; r s =–0.42; r s =–0.48, p < 0.05), respectively. More frequent hospitalizations and ER visits and longer LOS correlated significantly with worse fatigue (r s =0.51; r s =0.41; r s =0.53, p < 0.05), pain (r s =0.41; r s =0.38; r s =0.47, p < 0.05), physical function mobility (r s =–0.67; r s =–0.59; r s =–0.67, p < 0.05), depression (r s =0.38; r s =0.31; r s =0.42, p < 0.05), and social isolation (r s =0.76; r s =0.76; r s =–0.84, p < 0.05), respectively. Conclusions: We conclude that increased healthcare utilization in youth with SCD is associated with low adherence to hydroxyurea and worse HRQOL domain scores. It is important emphasize the clinical benefits of high adherence to hydroxyurea, particularly among youth with SCD. Future longitudinal studies are warranted to assess the directionality of these relationships, and may reveal modifiable behavioral factors associated with early changes in hydroxyurea adherence levels.",
keywords = "Sickle cell disease, adherence, healthcare utilization, hydroxyurea, quality of life",
author = "Badawy, {Sherif M} and Thompson, {Alexis A} and Holl, {Jane Louise} and Penedo, {Frank J.} and Liem, {Robert I}",
year = "2018",
month = "8",
day = "18",
doi = "10.1080/08880018.2018.1505988",
language = "English (US)",
volume = "35",
pages = "297--308",
journal = "Pediatric Hematology and Oncology",
issn = "0888-0018",
publisher = "Informa Healthcare",
number = "5-6",

}

Healthcare utilization and hydroxyurea adherence in youth with sickle cell disease. / Badawy, Sherif M; Thompson, Alexis A; Holl, Jane Louise; Penedo, Frank J.; Liem, Robert I.

In: Pediatric Hematology and Oncology, Vol. 35, No. 5-6, 18.08.2018, p. 297-308.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Healthcare utilization and hydroxyurea adherence in youth with sickle cell disease

AU - Badawy, Sherif M

AU - Thompson, Alexis A

AU - Holl, Jane Louise

AU - Penedo, Frank J.

AU - Liem, Robert I

PY - 2018/8/18

Y1 - 2018/8/18

N2 - Background: Sickle cell disease (SCD) complications lead to poor health-related quality of life (HRQOL) and increased healthcare utilization in this population, which could be mitigated with hydroxyurea therapy; however, adherence is suboptimal. We assessed the relationship of healthcare utilization to hydroxyurea adherence and HRQOL amongst youth with SCD. Methods: Thirty-four patients with SCD (median age 14 years, IQR 12–18) on hydroxyurea participated in this cross-sectional study and completed Morisky Adherence Scale 8-items and Patient Reported Outcomes Measurement Information System (PROMIS®) HRQOL measures. A medical chart review was conducted to assess healthcare utilization. Results: Participants with more frequent hospitalizations and emergency room (ER) visits and longer length of stay (LOS) had significantly lower fetal hemoglobin (r s =–0.44; r s =–0.45; r s =–0.46, p < 0.05) and mean corpuscular volume (r s =–0.47; r s =–0.42; r s =–0.48, p < 0.05), respectively. More frequent hospitalizations and ER visits and longer LOS correlated significantly with worse fatigue (r s =0.51; r s =0.41; r s =0.53, p < 0.05), pain (r s =0.41; r s =0.38; r s =0.47, p < 0.05), physical function mobility (r s =–0.67; r s =–0.59; r s =–0.67, p < 0.05), depression (r s =0.38; r s =0.31; r s =0.42, p < 0.05), and social isolation (r s =0.76; r s =0.76; r s =–0.84, p < 0.05), respectively. Conclusions: We conclude that increased healthcare utilization in youth with SCD is associated with low adherence to hydroxyurea and worse HRQOL domain scores. It is important emphasize the clinical benefits of high adherence to hydroxyurea, particularly among youth with SCD. Future longitudinal studies are warranted to assess the directionality of these relationships, and may reveal modifiable behavioral factors associated with early changes in hydroxyurea adherence levels.

AB - Background: Sickle cell disease (SCD) complications lead to poor health-related quality of life (HRQOL) and increased healthcare utilization in this population, which could be mitigated with hydroxyurea therapy; however, adherence is suboptimal. We assessed the relationship of healthcare utilization to hydroxyurea adherence and HRQOL amongst youth with SCD. Methods: Thirty-four patients with SCD (median age 14 years, IQR 12–18) on hydroxyurea participated in this cross-sectional study and completed Morisky Adherence Scale 8-items and Patient Reported Outcomes Measurement Information System (PROMIS®) HRQOL measures. A medical chart review was conducted to assess healthcare utilization. Results: Participants with more frequent hospitalizations and emergency room (ER) visits and longer length of stay (LOS) had significantly lower fetal hemoglobin (r s =–0.44; r s =–0.45; r s =–0.46, p < 0.05) and mean corpuscular volume (r s =–0.47; r s =–0.42; r s =–0.48, p < 0.05), respectively. More frequent hospitalizations and ER visits and longer LOS correlated significantly with worse fatigue (r s =0.51; r s =0.41; r s =0.53, p < 0.05), pain (r s =0.41; r s =0.38; r s =0.47, p < 0.05), physical function mobility (r s =–0.67; r s =–0.59; r s =–0.67, p < 0.05), depression (r s =0.38; r s =0.31; r s =0.42, p < 0.05), and social isolation (r s =0.76; r s =0.76; r s =–0.84, p < 0.05), respectively. Conclusions: We conclude that increased healthcare utilization in youth with SCD is associated with low adherence to hydroxyurea and worse HRQOL domain scores. It is important emphasize the clinical benefits of high adherence to hydroxyurea, particularly among youth with SCD. Future longitudinal studies are warranted to assess the directionality of these relationships, and may reveal modifiable behavioral factors associated with early changes in hydroxyurea adherence levels.

KW - Sickle cell disease

KW - adherence

KW - healthcare utilization

KW - hydroxyurea

KW - quality of life

UR - http://www.scopus.com/inward/record.url?scp=85060097628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060097628&partnerID=8YFLogxK

U2 - 10.1080/08880018.2018.1505988

DO - 10.1080/08880018.2018.1505988

M3 - Article

VL - 35

SP - 297

EP - 308

JO - Pediatric Hematology and Oncology

JF - Pediatric Hematology and Oncology

SN - 0888-0018

IS - 5-6

ER -